Diabetes Drug could work against Alzheimer's

November 24, 2010

Scientists from Berlin, Bonn and Dundee show in animal models that the diabetes drug Metformin has an effect against one of the main causes of the Alzheimer's disease.

Bonn, 24th November 2010. Metformin, a drug used in type 2-diabetes might have the potential to also act against Alzheimer's disease. This has been shown in a study from scientists of the German Center for Neurodegenerative Diseases (DZNE), the University of Dundee and the Max-Planck-Institute for Molecular Genetics. The researchers have found out that the diabetes drug metformin counteracts alterations of the cell structure protein Tau in mice nerve cells. These alterations are a main cause of the Alzheimer's disease. Moreover, they uncovered the molecular mechanism of metformin in this process. "If we can confirm that metformin shows also an effect in humans, it is certainly a good candidate for an effective therapy on Alzheimer's diseases," says Sybille Krauß from DZNE. Their results have been published in the scientific journal PNAS on November 22nd.

Alzheimer's disease is a form of dementia that affects almost exclusively elderly people. Today, about 700,000 people are suffering from Alzheimer's disease in Germany. Neurons in their brains die, leading to cognitive impairment. At the molecular level, the disease is characterized amongst others by the formation of Tau protein deposits in nerve cells. Tau is a molecule that usually binds to the supportive cytoskeleton and performs a function in the transport system of the cell. In Alzheimer's disease, Tau is tipped too strongly with phosphate groups. This phosphorylation causes removal of Tau from the cytoskeleton and aggregation.

To counteract this problem, researchers aimed at regulating the protein PP2A. This protein is normally responsible for removing phosphate groups from Tau protein. In Alzheimer's disease, PP2A is not active enough - leading to an increased phosphorylation and deposition of Tau. The scientists around Sybille Krauß and Susann Schweiger (University of Dundee) therefore looked for a drug that increases the activity of PP2A. "So far there is no drug on the market that targets the formation of tau aggregates," says Krauß.

In cell culture experiments with mouse nerve cells, the researchers showed that metformin directly protects PP2A against degradation by preventing the binding to special degradation proteins. This mechanism of metformin has been unknown so far. In addition, an increase in PP2A activity leads to a reduction in Tau phosphorylation. In a next step, the scientists added metformin to drinking water of healthy mice. This also led to a reduction of Tau-phoshorylation in brain cells. In further experiments, the researchers now intend to investigate, whether metformin prevents the deposition of tau proteins also in mouse models of Alzheimer's disease and improves cognitive performance of the animals. The effect in humans will then be tested in clinical studies. There is no risk of unexpected side effects, due to the fact that the drug is already used against diabetes.

German Center for Neurodegenerative Diseases (DZNE)

---

---

	Metformin - The Gold Standard: A Scientific Handbook by Clifford J. Bailey (Editor), Ian W. Campbell (Editor), Juliana C. N. Chan (Editor), Jaime A. Davidson (Editor), Harry C. S. Howlett (Editor), Patrick Ritz (Editor) Metformin may play in important role in the future in helping to prevent the development of diabetes: it is a strong candidate therapy for delaying the onset of the disease and potentially as part of a treatment programme to correct features of the metabolic syndrome.This book celebrates 50 years of research into metformin and its use in the treatment of diabetes.  Metformin is still the drug of choice for managing patients with type 2 diabetes and all new drugs are tested in comparison with this, the gold standard.  Comprising seven sections, addressing different aspects of research on metformin and its applications, this book is edited by a world class team of expert diabetologists and beautifully presented in two colour throughout.  It also includes a bibliography of all papers...
	Advantages of Extended-Release Metformin in Patients with Type 2 Diabetes Mellitus (DOI: 10.3810/pgm.2011.01.2241) (Postgraduate Medicine) by JTE Multimedia Metformin is a first-line pharmacological treatment for patients with type 2 diabetes mellitus because of its favorable overall profile, including its glucose-lowering ability, weight-neutral effects, and low risk of hypoglycemia; however, gastrointestinal (GI) intolerance may limit use in some patients. Extended-release metformin improves GI tolerability, allows once-daily dosing, and is currently available in multiple branded and generic formulations; however, it is more expensive than immediate-release metformin. Maximum plasma metformin concentrations are reached more slowly with the extended-release formulation compared with conventional immediate-release metformin, although both provide similar exposure at a given total daily dose. Extended-release metformin is as effective as...
	Effect of intensive lifestyle and metformin therapy on cardiovascular risk factors in patients with impaired glucose tolerance (Postgraduate Medicine) by JTE Multimedia The Diabetes Prevention Program (DPP) is the largest study to date proving that diet, exercise, and behavior modification help to prevent the development of type 2 diabetes mellitus (T2DM) in individuals at high risk. The DPP was a prospective, multicenter clinical trial in 3234 people with impaired glucose tolerance (IGT), comparing the effect of intensive lifestyle changes (diet and exercise) to treatment with standard diet and exercise combined with metformin (Diabetes Prevention Program Research Group, 2002). The intensive lifestyle changes aimed to reduce weight by 7% through a low-fat diet and 150 min of exercise per week. During the 3-year follow-up period, 29% of the placebo group developed T2DM compared with 14% of the intensive lifestyle change group and 22% of the metformin...
	Metformin shows little benefit in obese children.(Clinical Rounds): An article from: Pediatric News by Erik Goldman (Author) This digital document is an article from Pediatric News, published by Thomson Gale on June 1, 2006. The length of the article is 666 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Metformin shows little benefit in obese children.(Clinical Rounds) Author: Erik Goldman Publication: Pediatric News (Magazine/Journal) Date: June 1, 2006 Publisher: Thomson Gale Volume: 40 Issue: 6 Page: 32(1) Distributed by Thomson...
	Metformin (Glucophage). (Medication Update).(Brief Article): An article from: Southern Medical Journal by Mark Slagle (Author) This digital document is an article from Southern Medical Journal, published by Southern Medical Association on January 1, 2002. The length of the article is 472 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Metformin (Glucophage). (Medication Update).(Brief Article) Author: Mark Slagle Publication: Southern Medical Journal (Refereed) Date: January 1, 2002 Publisher: Southern Medical Association Volume: 95 Issue: 1 Page: 52(2) Article Type: Brief Article Distributed by Thomson...
	Impact of Metformin-Induced Gastrointestinal Symptoms on Quality of Life and Adherence in Patients with Type 2 Diabetes (Postgraduate Medicine) by JTE Multimedia Abstract: Aims Gastrointestinal (GI) symptoms are common in patients with type 2 diabetes mellitus (T2DM). This study assesses the impact of 1) metformin on GI symptoms and health-related quality of life (HRQoL) and 2) metformin-associated GI symptoms on medication adherence in patients with type 2 diabetes newly beginning therapy. Methods Patients with T2DM aged ≥ 18 years starting metformin from January to June 2007 who filled their prescriptions for ≥ 3 months were identified from a health benefits company database. Via telephone, GI symptom impact was evaluated in a 360-patient sample using the validated Bowel Symptom Questionnaire and Medical Outcomes Study 36-Item Short-Form Health (SF-36) survey. Adherence was assessed using the medication possession ratio (MPR). Logistic...
	Review of the Safety and Efficacy of Linagliptin as Add-On Therapy to Metformin in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled ... (Postgraduate Medicine) by JTE Multimedia Original article: Taskinen MR, Rosenstock J, Tamminen I, et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2011;13(1):65–74. PRACTICE PEARL: This trial in patients with type 2 diabetes inadequately controlled on metformin demonstrated the efficacy of adding linagliptin 5 mg once daily; this novel dipeptidyl peptidase-4 inhibitor significantly improved glycemic control without weight gain or increased risk of hypoglycemia. Original Publication Date: July 2011
	Metformin increases ovulation, cuts testosterone in PCOS patients. (Polycystic Ovary Syndrome).(polycystic ovary syndrome): An article from: Family Practice News by Timothy F. Kirn (Author) This digital document is an article from Family Practice News, published by International Medical News Group on August 15, 2002. The length of the article is 453 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Metformin increases ovulation, cuts testosterone in PCOS patients. (Polycystic Ovary Syndrome).(polycystic ovary syndrome) Author: Timothy F. Kirn Publication: Family Practice News (Magazine/Journal) Date: August 15, 2002 Publisher: International Medical News Group Volume: 32 Issue: 16 Page: 28(1) Distributed by Thomson...
	Metformin may reverse PCOS in some girls: two randomized trials show improvement in weight, lipid profiles of prepubertal patients.(Metabolic Disorders): An article from: Family Practice News by Michele G. Sullivan (Author) This digital document is an article from Family Practice News, published by International Medical News Group on January 1, 2005. The length of the article is 743 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Metformin may reverse PCOS in some girls: two randomized trials show improvement in weight, lipid profiles of prepubertal patients.(Metabolic Disorders) Author: Michele G. Sullivan Publication: Family Practice News (Magazine/Journal) Date: January 1, 2005 Publisher: International Medical News Group Volume: 35 Issue: 1 Page: 19(1) Distributed by...
	Metformin improves PCOS pregnancy outcomes: more trials urgently needed.(Women's Health)(polycystic ovary syndrome): An article from: Family Practice News by Kate Johnson (Author) This digital document is an article from Family Practice News, published by International Medical News Group on July 15, 2004. The length of the article is 673 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Metformin improves PCOS pregnancy outcomes: more trials urgently needed.(Women's Health)(polycystic ovary syndrome) Author: Kate Johnson Publication: Family Practice News (Magazine/Journal) Date: July 15, 2004 Publisher: International Medical News Group Volume: 34 Issue: 14 Page: 40(1) Distributed by Thomson...